Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Arvinas, Inc. (ARVN) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook suggesting a potential impact on its near-term stock price depending on actual results compared to estimates [1] Financial Expectations - The company is expected to post a quarterly loss of $1.48 per share, reflecting a year-over-year change of +3.9% [2] - Revenues are projected to be $33.75 million, which is an increase of 3.9% from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised 43.01% higher in the last 30 days, indicating a reassessment by analysts [2] - The Most Accurate Estimate for Arvinas is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +20.71% [5] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [4] - Arvinas currently holds a Zacks Rank of 3, indicating a potential for beating the consensus EPS estimate [5][6] Historical Performance - In the last reported quarter, Arvinas was expected to post a loss of $1.33 per share but actually reported a loss of $2.53, resulting in a surprise of -90.23% [7] - Over the past four quarters, the company has beaten consensus EPS estimates two times [7] Industry Context - In comparison, Moderna (MRNA) is expected to report a loss of $3.59 per share for the same quarter, indicating a year-over-year change of -1,989.5%, with revenues expected to decline by 93.3% [9] - Moderna's consensus EPS estimate has been revised down by 17.7% in the last 30 days, and it currently has an Earnings ESP of -6.17% [9]